Gut 2001;49:743-745 ( December )

Leading article

The putative role of inflammation in the irritable bowel syndrome

The first 150 words of the full text of this article appear below.

	Article

The irritable bowel syndrome (IBS) may be defined as a painful chronic abdominal symptom complex which is usually associated with altered bowel habit, and for which there is no discernible underlying structural abnormality. It is generally accepted that symptoms are generated by abnormalities of gut function, including altered sensory perception, abnormal motility and, in some patients, abnormalities of epithelial function. Behavioural factors are important, particularly in the reporting of symptoms. What is lacking is an understanding of the pathogenetic mechanisms that alter gut function. IBS is a heterogeneous condition, not only in its clinical presentation and pathophysiology, but also in terms of its pathogenesis. While both central and peripheral factors have been implicated in the pathogenesis of IBS, this article will restrict itself to an evaluation of the evidence supporting inflammation as a basis for altered gut function in IBS.

In considering the role of inflammation in . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Piche, T, Barbara, G, Aubert, P, Bruley des Varannes, S, Dainese, R, Nano, J L, Cremon, C, Stanghellini, V, De Giorgio, R, Galmiche, J P, Neunlist, M (2009). Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58: 196-201 [Abstract] [Full Text]  
• Piche, T, Saint-Paul, M C, Dainese, R, Marine-Barjoan, E, Iannelli, A, Montoya, M L, Peyron, J F, Czerucka, D, Cherikh, F, Filippi, J, Tran, A, Hebuterne, X (2008). Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 57: 468-473 [Abstract] [Full Text]  
• Motomura, Y, Ghia, J-E, Wang, H, Akiho, H, El-Sharkawy, R T, Collins, M, Wan, Y, McLaughlin, J T, Khan, W I (2008). Enterochromaffin cell and 5-hydroxytryptamine responses to the same infectious agent differ in Th1 and Th2 dominant environments. Gut 57: 475-481 [Abstract] [Full Text]  
• Wang, H., Steeds, J., Motomura, Y., Deng, Y., Verma-Gandhu, M., El-Sharkawy, R. T, McLaughlin, J. T, Grencis, R. K, Khan, W. I (2007). CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut 56: 949-957 [Abstract] [Full Text]  
• Distrutti, E., Sediari, L., Mencarelli, A., Renga, B., Orlandi, S., Russo, G., Caliendo, G., Santagada, V., Cirino, G., Wallace, J. L., Fiorucci, S. (2006). 5-Amino-2-hydroxybenzoic Acid 4-(5-Thioxo-5H-[1,2]dithiol-3yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity. J. Pharmacol. Exp. Ther. 319: 447-458 [Abstract] [Full Text]  
• Verdu, E F, Bercik, P, Verma-Gandhu, M, Huang, X-X, Blennerhassett, P, Jackson, W, Mao, Y, Wang, L, Rochat, F, Collins, S M (2006). Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55: 182-190 [Abstract] [Full Text]  
• Distrutti, E., Sediari, L., Mencarelli, A., Renga, B., Orlandi, S., Antonelli, E., Roviezzo, F., Morelli, A., Cirino, G., Wallace, J. L., Fiorucci, S. (2006). Evidence That Hydrogen Sulfide Exerts Antinociceptive Effects in the Gastrointestinal Tract by Activating KATP Channels. J. Pharmacol. Exp. Ther. 316: 325-335 [Abstract] [Full Text]  
• Li, C., Dandridge, K. S., Di, A., Marrs, K. L., Harris, E. L., Roy, K., Jackson, J. S., Makarova, N. V., Fujiwara, Y., Farrar, P. L., Nelson, D. J., Tigyi, G. J., Naren, A. P. (2005). Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions. JEM 202: 975-986 [Abstract] [Full Text]  
• Matthews, P J, Aziz, Q (2005). Functional abdominal pain. Postgrad. Med. J. 81: 448-455 [Abstract] [Full Text]  
• Vergnolle, N (2005). CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT. Gut 54: 867-874 [Full Text]  
• Isolauri, E, Rautava, S, Kalliomaki, M (2004). Food allergy in irritable bowel syndrome: new facts and old fallacies. Gut 53: 1391-1393 [Abstract] [Full Text]  
• Atkinson, W, Sheldon, T A, Shaath, N, Whorwell, P J (2004). Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 53: 1459-1464 [Abstract] [Full Text]  
• Collins, S (2004). Putative therapeutic targets in the treatment of visceral hyperalgesia. Gut 53: ii19-21 [Abstract] [Full Text]  
• Longstreth, G. F, Burchette, R. J (2003). Family practitioners' attitudes and knowledge about irritable bowel syndrome: Effect of a trial of physician education. Fam Pract 20: 670-674 [Abstract] [Full Text]  
• Stewart, T., Beyak, M. J, Vanner, S. (2003). Ileitis modulates potassium and sodium currents in guinea pig dorsal root ganglia sensory neurons. J. Physiol. 552: 797-807 [Abstract] [Full Text]  
• Afzal, N., Murch, S., Thirrupathy, K., Berger, L., Fagbemi, A., Heuschkel, R. (2003). Constipation With Acquired Megarectum in Children With Autism. Pediatrics 112: 939-942 [Abstract] [Full Text]  
• Buxton, D. B., Golomb, E., Adelstein, R. S. (2003). Induction of Nonmuscle Myosin Heavy Chain II-C by Butyrate in RAW 264.7 Mouse Macrophages. J. Biol. Chem. 278: 15449-15455 [Abstract] [Full Text]  
• Gwee, K-A, Collins, S M, Read, N W, Rajnakova, A, Deng, Y, Graham, J C, McKendrick, M W, Moochhala, S M (2003). Increased rectal mucosal expression of interleukin 1{beta} in recently acquired post-infectious irritable bowel syndrome. Gut 52: 523-526 [Abstract] [Full Text]  
• Gonsalkorale, W M, Perrey, C, Pravica, V, Whorwell, P J, Hutchinson, I V (2003). Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?. Gut 52: 91-93 [Abstract] [Full Text]